Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.…
Kura Oncology to Participate in Two Investor Conferences in November
Kura Oncology (NASDAQ: KURA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 260 employees.
The shares were at 6.910 USD on 20 November 2026, down 29.9% over 52 weeks. Its 52-week range is 6.750 USD to 13.66 USD: the price is 49.4% below the high and 2.4% above the low.
Its market capitalisation is 634.88M USD.
Kura Oncology reports return on equity of -160.0%, an operating margin of -394.3% and revenue up 10.1% year over year.
It holds more cash than debt, a net cash position of 466.27M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 11 March 2027.